Shire plc (SHPG) Tops Q2 EPS by 35c; Guides FY16 EPS Above Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Shire Delivers Strong Q2 2016 Revenue Growth; Upgrades Outlook
August 2, 2016 7:01 AM EDTDUBLIN, August 2, 2016 /PRNewswire/ --
Integration on track; operating cost synergy expectations increased Â
Pipeline progression continues with FDA approval of XIIDRA for dry eye diseaseÂ
Shire plc ("Shire") (LSE: SHP;NASDAQ: SHPG) announces unaudited results for the three months ended June 30, 2016, inclusive of the Baxalta transaction that closed on June 3, 2016.
Non GAAP Financial Highlights Q2 2016(1) Growth(1) CER(1)(2) Product sales $2,322 million +57% +58% Product sales excluding Baxalta products $1,763 million +19% +20% Total revenues $2,429 million +56% +57% US GAAP operating income from continuing operations $96 million (27%) Non GAAP operating income(2) $972 million +58% +57% US GAAP net income margin(3) (7%) (17pps)(4) Non GAAP EBITDA margin(2)... More